Interview 25 Oct 2017
What Could RNA Therapies Do for the Treatment of CNS Disorders?
Evelyn chatted with Thomas de Vlaam to find out what his company, Amylon, is working on and how it hopes…
Search Results for: CNS
News and Trends 23 Aug 2022
Gate Neurosciences emerges from stealth to tackle CNS diseases
Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system…
More News! 14 Nov 2022
Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease
Minoryx Therapeutics and Neuraxpharm Group have announced a strategic alliance for the European rights to a new therapy for rare…
Startup Scout 13 Oct 2017
This French Biotech is Taking On CNS Diseases of the Young and the Elderly
This week we're in Castres in the South of France to visit Neurolixis. This biotech is taking on diseases of…
ADVERTISEMENT
News and Trends 18 Oct 2022
Empyrean Neuroscience launches with $22M to target CNS disorders
Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a…
News and Trends 5 Jul 2022
EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS
EditForce, Inc. has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop and commercialize potential…
News and Trends 22 Sep 2022
Research identifies new treatment target for CNS injury and neurological disease
Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s…
News and Trends 29 Sep 2022
NeuShen Therapeutics closes $20M pre-A financing
Chinese biotech company NeuShen Therapeutics, Inc. has closed an approximately $20 million series pre-A financing led by LAPAM, a China…
News and Trends 7 Dec 2022
Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years
Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment…
News and Trends 25 Aug 2022
Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer
Patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases have completed their last visit…
News and Trends 13 Jul 2022
Sanofi sells two portfolios of established products to Neuraxpharma
Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical…
Interview 10 Jul 2017
Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease
I spoke with Marc Martinell, CEO of Minoryx, to learn first-hand how his company in Barcelona is bringing new hope…
News and Trends 10 Nov 2022
Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment
Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that…
News and Trends 30 Oct 2017
French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s
Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy,…
News and Trends 25 Jul 2022
Drug for acute treatment of social anxiety disorder did not meet primary endpoint
A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo…
News and Trends 12 Oct 2022
Virtual trials growth leads to Cambridge Cognition acquiring eClinicalHealth
Cambridge Cognition is looking to accelerate its growth through the acquisition of eClinicalHealth Ltd (eCH). Cambridge Cognition is an active…
ADVERTISEMENT
News and Trends 19 Dec 2017
Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner
Santa Claus is not the only busy one in the weeks leading up to Christmas this year, with Boehringer Ingelheim…
News and Trends 4 Mar 2015
Alkermes presents its new treatment of Alzheimer’s agitation
Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS)…
In Depth 31 Jan 2017
Biologicals on the Brain: Biotech in Neurodegenerative Disease
Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to…
News and Trends 2 Sep 2022
Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain
This week’s podcast guests are Mike McCully, CEO of Gate Neurosciences; Steven Evans, CEO and co-founder of Oncolyze; and Philipp…